FILE - The COVID-19 vaccine developed by Swedish-British manufacturer AstraZeneca is pictured in a file image. (Photo by Nicolas Armer/picture alliance via Getty Images) AdvertisementData disputes during ongoing studies typically remain confidential but in an unusual step, the National Institutes of Health publicly called on AstraZeneca to fix the discrepancy.AstraZeneca had been counting on findings from a predominantly U.S.
study of 32,000 people to help rebuild confidence in a vaccine that, despite being widely used in Britain, Europe and other countries, has had a troubled rollout.
Previous studies have turned up inconsistent data about its effectiveness, and then last week a scare over blood clots had some countries temporarily pausing.